Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 161Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 95Colonic Neoplasms 46Rectal Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 29Carcinoma, Squamous Cell 25Pancreatic Neoplasms 18Neoplasms 18Esophageal Neoplasms 18Lung Neoplasms 17Stomach Neoplasms 13Laryngeal Neoplasms 12Recurrence 11Oropharyngeal Neoplasms 11Mouth Neoplasms 11Esophageal Squamous Cell Carcinoma 11Colorectal Cancer Metastatic 10Tongue Neoplasms 9Carcinoma 9Breast Neoplasms 9Nasopharyngeal Carcinoma 8Hypopharyngeal Neoplasms 8Adenocarcinoma Of Esophagus 8Laryngeal Diseases 6Salivary Gland Neoplasms 5Neoplasms, Squamous Cell 5Glioblastoma 5Uterine Cervical Neoplasms 4

Interventions

Oxaliplatin 3regorafenib 2Irinotecan 2Drug Therapy 2Cetuximab 2Capecitabine 2trifluridine tipiracil drug combination 1surufatinib 1raltitrexed 1paclitaxel poliglumex 1nimotuzumab 1endostar protein 1durvalumab 1defactinib 1aflibercept 1Panitumumab 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Colorectal Cancer × Cetuximab × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT00637091 2021-01-22

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Asan Medical Center

Phase 2 Completed
40 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡